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Our previous reports demonstrated that NAC1, a BTB/POZ domain-containing nuclear protein, upregulates in recurrent ovarian
serous carcinoma and participates in developing drug resistance in cancer cells. The current study applies quantitative proteomics
to identify the proteins controlled by NAC1 by comparing the proteomes of SKOV3 cells with and without expression of a
dominant negative NAC1 construct, N130. From the proteins that are downregulated by N130 (upregulated by NAC1), we chose
to further characterize fatty acid synthase (FASN). Similar to change in protein level, the FASN transcript level in SKOV3 cells
was signiﬁcantly reduced by N130 induction or by NAC1 knockdown. Immunohistochemistry showed that NAC1 and FASN
immunointensities in ovarian serous carcinoma tissues had a highly signiﬁcant correlation (P<. 0001). Moreover, we found
that recurrent serous carcinomas exhibited higher FASN immunointensities than their matched primary tumors (P<. 001).
Multivariate analysis showed that an FASN staining score of >1 in serous carcinomas was associated with a worse overall survival
time (P<. 01). Finally, C93, a new FASN inhibitor, induced massive apoptosis in carboplatin/paclitaxel resistant ovarian cancer
cells. In conclusion, we show that NAC1 is essential for FASN expression in ovarian serous carcinomas and the expression of FASN
signiﬁcantly correlates with tumor recurrence and disease aggressiveness. The dependence of drug resistant tumor cells on FASN
suggests a potential application of FASN-based therapeutics for recurrent ovarian cancer patients.
1.Introduction
Ovarian cancer is a neoplastic disease that exempliﬁes
many of the major issues underlying current chemotherapy
regimens in clinical oncology [1, 2]. Although most ovarian
carcinomas at advanced stages are responsive to initial
carboplatin and paclitaxel treatment, tumor clones resistant
to these drugs eventually evolve as recurrent diseases. As
a consequence, the main contributors to the mortality
and morbidity of advanced stage ovarian cancer patients
are chemoresistant tumors. In an eﬀort to elucidate the
molecular mechanisms underlying chemoresistance, we have
studied ovarian cancer genome and transcriptome and have
identiﬁed several genes and pathways that are potentially
involved in this phenotype. One of these genes, NACC1
encoding NAC1 (or NAC-1) protein, shows signiﬁcantly
higherexpressioninrecurrentchemoresistantovarianserous
carcinomas than in primary untreated tumors [3]. NACC1
belongs to the BTB/POZ domain gene family and contains
the BEN domain that potentially mediates protein-DNA and
protein-protein interactions during chromatin organization
and transcription [4]. Biologically, NAC1 has been demon-
strated to be an embryonic stem cell marker that controls
proliferation and pluriopotency in embryonic stem cells2 Journal of Oncology
[5–7]. NAC1 homodimerizes through the highly conserved
BTB/POZ domain (a.a. from 1–129) [8] and its complex
formation is essential for a variety of its biological functions.
In our previous study, we found that recurrent ovarian
serous carcinomas showed a higher NAC1 expression level
than their matched primary untreated tumors [3, 9]. Ectopic
expression of NAC1 increased paclitaxel resistance while
knockdown of NAC1 or disruption of NAC1 homodimer-
ization sensitized cancer cells to chemotherapeutic drugs
[3, 9]. In order to understand how NAC1 contributes to
drug resistance, we previously compared the gene expression
proﬁles of SKOV3 ovarian cancer cells to those of NAC1
inactivated SKOV3 cells where the inactivation was induced
by expression of N130, a mutant protein containing only
the BTB/POZ domain of NAC1 that competitively inhibits
NAC1 homodimerization. We found that NAC1 negatively
regulated the components of the Gadd45 tumor suppres-
sor pathway including Gadd45α and its binding protein,
Gadd45gip1 [9, 10]. However, suppressing the Gadd45
tumorsuppressorpathwaydidnotcompletelyrescueovarian
cancer cells after NAC1 inactivation, thus suggesting that
other mechanisms also play a role.
In this study, we identiﬁed proteins that are potentially
regulated by NAC1 by applying a quantitative proteomic
method using tandem mass spectrometry (MS/MS) and
spectral count [11]. A total of 2914 proteins were identiﬁed.
To reduce the sampling error and increase the quantiﬁcation
accuracy, 208 proteins identiﬁed by at least 20 spectra and
two unique peptides were quantiﬁed to identify candidate
proteins controlled by N130 expression. By comparing the
protein quantity in the proteomes between N130-induced
and noninduced SKOV3 cells, we identiﬁed new NAC1
regulated proteins that could be responsible for the NAC1-
mediated drug resistance and for other biological functions.
Among the proteins found to be downregulated in N130-
induced cells, we selected fatty acid synthase (FASN) for
further characterization because it has been shown to be
associatedwithtumorprogressioninavarietyofhumancan-
cers and its inhibitors are available for potential translation
studies.
2. Methods
2.1. Cell Lines and Clinical Tissue Samples. High-grade
ovarian carcinoma cell lines, SKOV3, A2780, and OVCAR3,
were obtained from the American Type Culture Collection
(Rockville, MD), and a low-grade serous cell line, MPSC1,
was previously established by us [12]. OSE10 was as SV-
40-immortalized ovarian surface epithelial cell line. All
cell lines were maintained in RPMI media with 5% heat-
inactivated fetal bovine serum (HyClone, Logan, UT) and
2% penicillin/streptomycin (Gibco, Rockville, MD).
A total of 427 ovarian carcinoma tumors collected
between January 1990 and December 2006 were arranged in
tissue microarrays. These included 269 high-grade serous,
45 low-grade serous, 45 endometrioid, and 68 clear cell
carcinomas. Fifteen histologically normal ovarian tissues
and 20 benign ovarian serous cystadenomas collected over
the same period were also analyzed. For Kaplan-Meier
survival analysis, we included 184 primary high-grade serous
carcinoma patients who underwent optimal primary cytore-
ductive surgery followed by platinum-based chemotherapy
at the Johns Hopkins Hospital. The paraﬃnt i s s u e sw e r e
obtained from the surgical pathology repository at the Johns
Hopkins Hospital and clinical data was obtained from medi-
calrecords,including age,race,stage,histologic subtype,and
date of patient’s current status (alive or deceased). Median
follow-up in those patients was 44.7 months. A subset of 56
high-grade serous carcinomas including 28 pairs of matched
primary and recurrent tumors was analyzed to correlate
FASN expression levels and to evaluate primary/recurrent
tumor status. Another subset of 162 high-grade serous
carcinomas was analyzed for correlation of NAC1 and FASN
expression levels because the NAC1 immunostaining slides
from these cases were available from our previous study
[3]. Collection of tissue samples was in accordance with the
guidelines of the institutional review board.
2.2. Quantitative Proteomics. Cell lysates were collected 48
hours after induction (removal of doxycyclin) or mock
induction [3]. Protein concentration was measured by BCA
assay. The same amounts of proteins (1mg) from each
condition were reduced, alkylated, and digested with 1 to 50
Trypsin/protein ratio at 37
◦C overnight. The peptides were
puriﬁed with C18 columns and resuspended in water with a
ﬁnal concentration of 10μg/μL.
For protein identiﬁcation and quantiﬁcation, each pep-
tide mixture was analyzed twice by the LTQ ion trap
mass spectrometer (Thermo Finnigan, San Jose, CA). For
each analysis, 2μg of peptides were injected into a peptide
cartridge packed with C18 resin, and then passed through
a1 0 c m× 75μm i.d. microcapillary HPLC (μLC) column
packed with C18 resin. A linear gradient of acetonitrile from
5%–32% over 100minutes at ﬂow rate of ∼300nL/min was
applied. During the LC-MS mode, data was acquired in the
m/z range of 400 and 2000. The MS/MS was also turned on
to collect CID using data dependent mode.
MS/MSspectraweresearchedwithSEQUESTagainstthe
humanIPIproteindatabase(version2.28).Thepeptidemass
tolerance is 3.0Da. Other parameters of database searching
are as follows: cysteine modiﬁcation (add cysteine 57) and
oxidized methionine (add methionine with 16 Da). The
output ﬁles were evaluated by INTERACT [13] and Peptide
Prophet [14]. The identiﬁed peptides with a probability
score ≥ 0.9 were used for the spectral count. To determine
the number of MS/MS spectra used for identiﬁcation of
e a c hp r o t e i ni nd i ﬀerent conditions using our in-house
developed software tool and to reduce the error for protein
identiﬁcation and quantiﬁcation using MS/MS spectra, we
only quantiﬁed proteins identiﬁed by at least 20 spectra
and 2 independent peptides from the N130-induced and-
noninduced cells.
2.3. Western Blot and Real Time PCR. Western blot analysis
was performed on the protein lysates prepared from ovarian
cancer cell lines and OSE10. Similar amounts of totalJournal of Oncology 3
proteinfromeachlysatewereseparatedon10%T ris-Glycine-
SDS polyacrylamide gels (Novex, San Diego, CA) and then
electroblotted to Millipore Immobilon-P polyvinylidene
diﬂuoride membranes. The membranes were probed with an
anti-FASN mouse monoclonal antibody (1:100) (FASgen,
Baltimore, MD) followed by a peroxidase-conjugated goat
antimouse immunoglobulin (1:6,000). Western blots were
developed by chemiluminescence (Pierce, Rockford, IL)
utilizing glyceraldehyde-3-phosphate dehydrogenase as the
loading control. To determine the mRNA levels of FASN,
we performed quantitative real-time PCR using a BioRad
iCycler. Total RNA was isolated with the TRIzol method
(Invitrogen) and cDNA was synthesized from 2 to 5μgt o t a l
RNA. FASN primer sequences were 5 -CATCCAGATAGG-
CCTCATAGAC-3  (forward) and 5 -CTCCATGAAGTA-
GGAGTGGAAG-3  (reverse). The expression of FASN was
normalized to that of human amyloid beta precursor protein
based with threshold cycle numbers calculated from dupli-
cate measurements. Mean fold expression diﬀerences were
further normalized to those of ovarian surface epithelium,
OSE10.
2.4. Immunohistochemistry. For immunohistochemistry,
paraﬃns e c t i o n sa f t e rd e p a r a ﬃnization were incubated with
a primary antimouse FASN antibody at a dilution of 1:50 in
a4 ◦C moist chamber overnight. Negative controls included
benign serous cystadenomas and normal ovaries. Two
independent observers scored the FASN immunoreactivity
using a categorical scoring system from 0 (not detectable) to
3 (intense) with the mean score recorded from triplicates.
Among the FASN stained cases, there were 162 that had been
previously stained with an anti-NAC1 antibody [3, 15].
2.5. Cell Number and Apoptosis Detection. Cancer cells were
seeded in 96-well plates at 2.5 × 103 cells/well for 24hours
and then were incubated with 100μL of the FASN inhibitor,
C93, at concentrations ranging from 2.5μg/mL to 50μg/mL
for 48 hours. After incubation, the number of viable
cells was measured by the CellTiter-Blue assay (Promega,
Madison, WI). These numbers were plotted against FASN
inhibitor concentrations, and the value of IC50 (i.e., the
C93 concentration at which cell growth dropped to 50% of
the control level) was estimated. To detect early apoptotic
c e l l s ,w eg r e wo v a r i a nc a n c e rc e l ll i n e si n6w e l lp l a t e s( 5×
105 cells/well) and treated them with C93 at their IC50 and
with DMSO of equal concentration. The early apoptotic cells
were quantiﬁed utilizing the Annexin V-FITC detection kit
(Biovision, Mountain View, CA) and annexin V-stained cells
were determined by ﬂow cytometry.
After treating cells with C93 or DMSO, cells were
trypsinized, washed, and resuspended in a solution contain-
ing0.6%NP-40,3.7%formaldehyde,and11mg/mLHoechst
33258 in a phosphate buﬀered solution. The stained cells
were then quantiﬁed by the BD LSR cytometer (Becton
Dickinson, Franklin Lakes, NJ). Cell cycle analysis was
performed using the CellQuest software (Becton Dickinson)
and cells in the subG1 phase that represent the late phase of
apoptosis were also measured.
2.6. Lentivirus Production and Transduction. Two NAC1
targetingshRNAplasmidspreviouslyclonedintothepLKO.1
(Sigma) and the packaging lentivirus plasmids were cotrans-
fected into 293FT cells using Lipofectamine 2000 (Invit-
rogen. The sequences of NAC1 targeting shRNAs were
5 -CCGGCCCAAGTGAGATTG CACATTTCTCGAGAAA-
TGTG CAATCTCACTTGGGTTTTTTG-3  (shRNA-A) and
5 -CCGG CAAGTACTACTGCC AGAACTTCTCGAG AA-
GTTCTGGCAGTAGTACTTGTTTTTTG-3  (shRNA-C).
Five hours after incubation, the transfection reagents were
replaced with 10% FBS RPMI culture media supplemented
with bovine serum albumin. The virus-containing super-
natant was collected, the mixture was centrifuged, and
polybrene was added to a ﬁnal concentration of 8μg/mL.
Transduction was carried out by adding 0.25mL of virus
supernatant to the SKOV3 cells. A second transduction was
performed 24hours later using the same protocol. shRNA or
control (vector only) virus transduced cells were enriched
by adding 2μg/mL of puromycin. Following this second
roundoftransduction,cellswerecollectedat48and72hours
for quantitative real-time PCR analysis of NAC1 and FASN
mRNA expression levels.
3. Results
3.1. High-Throughput Quantitative Proteomics Identiﬁes
FASN as an NAC1-Regulated Protein. To determine the pos-
sible mechanism by which NAC1 promotes drug resistance,
we used the quantitative proteomics to compare the pro-
teomes of N130-induced and-noninduced SKOV3 ovarian
cancer cells using tandem mass spectrometry (MS/MS) and
spectral count [11]. We were able to identify proteins that
corresponded to a total of 2914 proteins. To reduce the sam-
plingerrorandincreasethequantiﬁcationaccuracy,208pro-
teinsidentiﬁedbyatleast20spectraandtwouniquepeptides
were quantiﬁed to identify candidate proteins controlled by
N130 expression. Based on the protein expression ratio of
N130 noninduced to N130 induced cells (N130 OFF versus
N130 ON), we listed the 19 proteins whose abundances
were at least increased 50% (OFF/ON ≥ 1.5, Table 1)a n d
identiﬁed 18 proteins whose levels were at least increased
50% (ON/OFF ≥ 1.5) by N130 induction (Table 1).
Cells with induced expression of N130 showed signiﬁcantly
higher levels NAC1 expression than N130-noninduced cells
(ON/OFF = 76.5), and all the identiﬁed peptides from
NAC1matchedtheN130(BTB/POZ)domain,indicatingthe
robustness of N130 induction. Since our primary interest
was to identify the proteins that are upregulated by NAC1
(i.e.,downregulatedbyN130),weselectedfattyacidsynthase
(FASN) for validation and characterization since its level
in noninduced cells is 1.57 times that in induced cells. We
made this choice because, more than other proteins in the
list, FASN has been associated with tumor progression and
because speciﬁc inhibitors of FASN are available for further
studies. The levels of FASN are less abundant in N130
induced cells than in N130-noninduced cells, suggesting
that NAC1 inactivation by N130 suppresses FASN protein
expression in SKOV3 cells.4 Journal of Oncology
Table 1: Proteins that are diﬀerentially expressed in N130-induced and-noninduced SKOV3 cells.
(a) Proteins downregulated by N130 induction
IPI Protein name ON-
spectra
ON-
peptides
OFF-
spectra
OFF-
peptides
Total
spectra Oﬀ/on
IPI00013881 Heterogeneous nuclear
ribonucleoprotein H 4 5 20 7 24 4.62
IPI00012388 Transcription intermediary
factor 1-beta 8 7 23 9 31 3.07
IPI00220985 Keratin, type I cytoskeletal 18 8 4 18 5 26 2.35
IPI00298547 RNA-binding protein regulatory
subunit 10 7 23 7 33 2.30
IPI00299571 Protein disulﬁde isomerase A6 11 3 21 8 32 1.91
IPI00216976 aldolase C,
fructose-bisphosphate 10 3 19 4 29 1.90
IPI00012074 Heterogeneous nuclear
ribonucleoprotein R 9 5 17 7 26 1.89
IPI00013917 40S ribosomal protein S12 10 3 19 3 29 1.85
IPI00297779 T-complex protein 1, beta
subunit 10 5 18 8 28 1.80
IPI00027434 Transforming protein RhoC 8 5 14 5 22 1.75
IPI00141318 P63 protein 8 6 13 5 21 1.73
IPI00219217 lactate dehydrogenase B 11 6 18 8 28 1.67
IPI00219096 high-mobility group box 1 15 4 25 5 40 1.67
IPI00009236 Caveolin-1 9 2 15 2 24 1.67
IPI00328343 Probable ATP-dependent RNA
helicase p47 11 6 18 6 29 1.64
IPI00302927 T-complex protein 1, delta
subunit 8 3 13 6 21 1.63
IPI00328188 fatty acid synthase 21 7 33 11 54 1.57
IPI00015027 AHNAK-related protein 11 7 17 11 27 1.55
IPI00017617 Probable RNA-dependent
helicase p68 11 8 17 7 28 1.50
(b) Proteins upregulated by N130 induction
IPI Protein name ON-
spectra
ON-
peptides
OFF-
spectra
OFF-
peptides
Total
spectra On/oﬀ
IPI00017454 Hypothetical protein FLJ13940 23 4 0 0 23 ?
IPI00045207 NAC1 protein 153 9 2 1 155 76.50
IPI00395440 Unknown 26 5 5 4 31 5.13
IPI00107117 Peptidylprolyl isomerase B 14 5 6 3 20 2.33
IPI00290566 T-complex protein 1, alpha
subunit 1 4 6632 0 2 . 3 3
IPI00176692 similar to Heterogeneous nuclear
ribonucleoprotein A1 27 5 12 6 39 2.25
IPI00221088 ribosomal protein S9 17 6 8 6 25 2.13
IPI00215918 ADP-ribosylation factor 4 17 7 9 7 26 1.89
IPI00015786 Spectrin alpha chain, brain 53 27 30 18 83 1.77
IPI00152412 Hypothetical protein 14 4 8 5 22 1.75
IPI00020984 Calnexin 29 10 17 7 46 1.71
IPI00010896 Chloride intracellular channel
protein 1 17 5 10 4 27 1.70
IPI00027626 T-complex protein 1, zeta
subunit 18 9 11 9 29 1.64
IPI00216587 40S ribosomal protein S8 13 6 8 6 21 1.63Journal of Oncology 5
(b) Continued.
IPI Protein name ON-
spectra
ON-
peptides
OFF-
spectra
OFF-
peptides
Total
spectra On/oﬀ
IPI00216318 tyrosine 3-monooxygenase 40 10 25 9 65 1.58
IPI00329351 60 kDa heat shock protein,
mitochondrial 66 21 44 17 110 1.52
IPI00217468 H1 histone family, member 5 21 5 14 4 35 1.50
IPI00291006 Malate dehydrogenase,
mitochondrial 15 6 10 4 25 1.50
Table 2: Immunointensities of NAC1 and FASN in high-grade
serous carcinoma.
FASN 2+/3+ FASN 0/1+
NAC1 intense 51 34
NAC1 weak 19 58
Total (n)7 09 2
Table 3: FASN immunointensity in primary and recurrent ovarian
serous carcinomas.
Score
Tumor 0/1+ 2+/3+
Primary 18 10
Recurrent 4 24
Total (n)2 2 3 4
χ2P<. 0001.
3.2. Validation of NAC1-Dependent FASN Expression. To
validate the proteomic result above, we used quantitative
real-time PCR to determine FASN transcript levels in two
independent experimental systems. In our ﬁrst system,
we used the same NAC1 dominant negative (N130) cell
model that was used in the proteomic analysis to assess
whether disruption of NAC1 homodimerization by N130
leads to a decrease in FASN mRNA level. We observed that
N130mRNA,asdetectedbyaPCRprimerpairthatampliﬁes
the N130 region, increases 48 and 72 hours after induction
(Figure 1(a)). At these same time points, SKOV3 cells with
N130 induction exhibit a downregulation of FASN mRNA.
Of note, at 48hours after N130 induction, the decrease
in FASN expression is similar between mRNA (46%) and
protein (36%) levels. In our second system, we knocked
down NAC1 in SKOV3 cells to determine the FASN levels.
Two NAC1 shRNAs (shRNA-A and -C) that target diﬀerent
coding regions of NACC1 were designed and packaged
into lentivirus. We found that both shRNAs eﬀectively
reduce NAC1 transcript levels (to less than 10% of control)
after transduction with shRNA lentivirus (Figure 1(b)).
Correspondingly, FASN expression levels also decrease as
compared to control. The above ﬁndings from cell culture
systems suggest that NAC1 expression and its dimerization
domain are essential for maintaining FASN expression in
tumor cells.
In order to assess the biological signiﬁcance of NAC1-
dependent FASN expression, we stained tumor samples
obtained from ovarian cancer ascites and tissues for NAC1
and FASN and correlated their immunointensities. The
speciﬁcity of the anti-NAC1 has been demonstrated previ-
ously [3] and the speciﬁcity of the anti-FASN monoclonal
antibody is shown in Figure 2(a). Western blot analysis
shows a single protein band at the molecular mass of FASN
protein in all three ovarian cancer cell lines (OVCAR3,
A2780, and SKOV3) but not in a low-grade serous carci-
noma cell line, MPSC1, nor in ovarian surface epithelial
cells (OSE10). Analyzing 162 high-grade serous carcinomas
showed a signiﬁcant positive correlation in NAC1 and
FASN immunointensities (P<. 0001, Fisher Exact test)
(Table 2). These immunointensities for four representative
high-grade serous carcinomas are shown in Figure 2(b).O u r
observations support the view that FASN expression is at
least in part regulated by NAC1.
3.3. FASN Expression in Ovarian Serous Tumors. To extend
the above immunostaining ﬁndings, we investigated FASN
immunoreactivity in various types of ovarian tumors. All
benign cystadenomas and normal ovarian surface epithe-
lium (n = 35) display undetectable to very low FASN
staining (mean score = 0) whereas ovarian carcinomas of
various histologic subtypes show FASN immunoreactivity
(mean score ≥ 1) in most cases (Figures 2(c) and 2(d)).
The FASN staining score of high-grade serous carcino-
mas is signiﬁcantly higher than that of low-grade serous
carcinomas (P<. 0001, t-test) and normal ovaries and
benign cystadenomas (P<. 0001). The FASN score in high-
grade serous carcinomas is marginally higher than that in
clear cell carcinoma (P = .024) and there is no statistical
signiﬁcance of FASN score between high-grade serous and
endometrioid carcinoma (P = .099). Since NAC1 has
been shown to be highly expressed in recurrent rather than
primary high-grade ovarian serous carcinomas, we expect
that FASN expression levels will follow the same pattern. To
test this possibility, we assessed the FASN immunoreactivity
of matched primary and ﬁrst recurrent tumors from the
same individuals. As expected, the FASN staining score is
signiﬁcantly higher in recurrent than in primary tumors
(P<. 0001, paired t-test) (Figure 3(a)). Based on a
2 × 2 contingency table and chi-square analysis, we also
found that recurrent tumors exhibit a higher percentage of
cases with intense FASN immunoreactivity than primary
tumors do (Table 3). Figure 3(b) illustrates representa-
tive pairs of primary and recurrent tumors with FASN
stain.6 Journal of Oncology
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Figure 1: NAC1-dependent FASN expression in ovarian cancer cells. (a) N130 mRNA, as detected by a PCR primer pair that ampliﬁes the
N130region,increases after N130induction.In contrast,FASNmRNAdecreases 48and72hoursafter induction.(b)AftershRNAlentivirus
t r a n s d u c t i o n ,b o t hs h R N A s( - Aa n d- C )e ﬀectively reduce NAC1 transcript levels to less than 10% of control and reduce FASN expression.
3.4. Clinical Signiﬁcance of FASN Expression in High-Grade
Ovarian Serous Carcinomas. To evaluate the clinical signif-
icance of FASN expression, we correlated the expression
levels in primary high-grade serous carcinoma tumors
with overall survival of the patient. We found that higher
FASN staining scores (scores > 1) correlated with worse
overall survival (P<. 002) (Figure 3(c)). Patients with
primary tumors that showed minimal or undetectable FASN
immunoreactivity (score ≤ 1) had a median survival time
of 60.4 months (range 1–193 months), whereas those with
tumors that showed positive immunoreactivity (score > 1)
had a median survival time of 36.9 months (range 1–140
months, P<. 01). After adjusting for age, stage, and race
in a multivariate analysis, we found that, in patients with
primary serous carcinomas, FASN expression remains an
independentmarkerforprognosiswithahazardratioof1.87
(95% CI: 1.12–3.11, P = .02).
3.5. C93 Suppresses Growth of Paclitaxel-Resistant and Car-
boplatin-Resistant Ovarian Cancer Cells. The above ﬁndings
suggest that FASN preferentially expresses in recurrent and
in most aggressive types of ovarian serous carcinomas,
raising the possibility that FASN expression contributes to
this phenotype. Thus, to determine if FASN expression
is essential for cell growth and survival of high-grade
serous carcinoma cells (including those that are resistant
to paclitaxel or carboplatin), we applied C93, a second
generation FASN inhibitor, to ovarian cancer cell lines
(including SKOV3, A2780, and OVCAR3). We ﬁrst used the
cell number counted by CellTiter Blue assay to determine
the IC50 of C93 for each ovarian cancer cell line. The
IC50 of C93 was 7.4μg/mL, 7.4μg/mL, and 8.7μg/mL
for parental, paclitaxel, and carboplatin resistant SKOV3
cells, respectively; 7.4μg/mL, 7.5μg/mL, and 8.4μg/mL for
parental, paclitaxel, and carboplatin resistant A2780 cells,
respectively; and 8.6μg/mL, 6.5μg/mL, and 8.8μg/mL for
parental, paclitaxel, and carboplatin resistant OVCAR3 cells,
respectively. When applied to each cell line at its IC50
concentration, C93 signiﬁcantly increases the percentage of
annexin V stained cells (representing the early phase of
apoptosis) and the sub-G1 fraction in cell cycle analyses
(representing the late phase) (Figure 4). Thus, C93 induces
apoptosisinallthreeovariancancercelllines.Thenumberof
annexinV-stainedcellsincreasesinatimedependentfashion
in all cancer cell lines including those resistant to carboplatin
and paclitaxel (Figure 4(b)). Moreover, paclitaxel resistant
cells are more sensitive to C93 than carboplatin resistant
cells, especially in the A2780 and SKOV3 cell lines. In all
three cell lines, the C93-treated group shows a signiﬁcantly
higher percentage of sub-G1 cells than the DMSO-treated
group (P<. 01). These sub-G1 cells can be detected as
early as 12 hours after C93 treatment and become more
pronounced by 48 hours (Figure 4(c)). C93 fails to aﬀect cell
cycle progression in SKOV3 and OVCAR3 cells by 96 hours
after treatment but it arrests A2780 cells in the G1 phase as
early as 24 hours after treatment (data not shown).
4. Discussion
One of the major challenges facing ovarian cancer patients is
the development of chemoresistant tumors after cytoreduc-
tionsurgeryandchemotherapy.Inthisstudy,weprovidenew
evidence that homodimerization of NAC1, a drug resistance-
associated nuclear protein, is essential for maintaining FASNJournal of Oncology 7
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Figure 2: Expression of NAC1 and FASN in ovarian tumor tissues. (a) Western blot analysis shows a single protein band that corresponds
to FASN protein in all three ovarian cancer cell lines (OVCAR3, A2780, and SKOV3) but not in a low-grade serous carcinoma cell line
(MPSC1) nor in ovarian surface epithelial cells (OSE10). (b) Immunoreactivity of NAC1 (upper panels) and FASN (bottom panels) in four
representative high-grade serous carcinomas. For each staining, the immunostaining scores are shown in the upper left corner (c)-(d). FASN
expression in diﬀerent types of ovarian carcinomas. (c) FASN immunointensity scores for diﬀerent types of ovarian carcinoma including
high-grade serous, low-grade serous, clear cell, and endometrioid carcinomas. The mean and standard deviation of the immunostaining
score are shown. (d) Representative tumor sections of FASN immunostaining are illustrated. FASN immunoreactivity is detectable in high-
grade serous carcinoma cells but not in normal ovarian surface epithelium nor in cystadenomas.
expression at both protein and mRNA levels in ovarian
cancer cells. We also demonstrate that FASN expression
is highly correlated with the status of recurrent chemore-
sistant ovarian serous carcinomas and is independently
correlated with poor overall survival. Suppressing FASN
enzymeactivitywithitsinhibitorinducesapoptosisincancer
cells that are resistant to paclitaxel and carboplatin. Thus,
molecularstudiesthatilluminatethefundamentalproperties
of chemoresistance should provide new therapeutic targets
for treating recurrent ovarian cancers.
MammalianFASNisa ∼260kDcytoplasmicenzymethat
isresponsibleforallthestepsofdenovofattyacidsynthesis.It
catalyzes the NADPH-dependent condensation of malonyl-
CoA and acetyl-CoA to palmitate [16]. Importantly, normal
adult tissues express minimal amounts of FASN due to
the presence of abundant dietary lipids. In contrast, a
variety of tumors including breast, colon, ovary, and prostate
cancer express elevated FASN levels [17–23], since tumor
cells become less sensitive to regulatory nutritional signals
and prefer the de novo lipogenesis pathway. Furthermore,8 Journal of Oncology
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Figure 3: Clinical signiﬁcance of FASN expression in high-grade ovarian serous carcinoma. (a) Comparison of FASN immunointensity
scores for 28 pairs of matched primary and recurrent tumors from the same patients. Recurrent tumors exhibit elevated expression when
compared to primary specimens from the same patient (P<. 0001). (b) FASN staining of the primary and recurrent tumors from two
representative patients. (c) Kaplan-Meier curve analysis shows that patients whose tumors exhibit higher FASN immunostaining scores
have signiﬁcantly shorter survival times than those whose tumors show undetectable or very low FASN immunoreactivity (60.4 versus 36.9
months, P<. 01).
FASN expression level highly correlates with the clinical
aggressiveness of tumors [17, 18, 24–27].
Although previous reports have shown the role of FASN
expression in ovarian cancer [18, 28], the current study
provides new ﬁndings that should have several biological
and clinical implications. First, we use in vitro cell culture
studies using NAC1 targeting shRNAs and the dominant
negative NAC1 (N130) approach to demonstrate that FASN
is one of the proteins regulated at least in part by NAC1.
This NAC1-dependent FASN expression in protein level
is further supported by its mRNA level and the positive
correlation between NAC1 and FASN immunointensities
in ovarian serous carcinoma samples. The mechanism
underlying upregulation of FASN in human cancer is not
clear and it likely involves multiple pathways. Previous
studies have shown that, in prostate cancer, caveolin-1 and
KLF5/SREBP-1 function upstream of FASN [29, 30]. Thus,
at least in ovarian cancer cells, the NAC1 pathway represents
another mechanism for controlling FASN expression. Unlike
other members of the BTB/POZ family, NAC1 lacks the
zinc ﬁnger DNA-binding domain. Rather, it has been
reported to act as a transcription corepressor with other
BTB/POZ proteins [31]. Moreover, it has also been shown
to interact with nuclear proteins potentially involved in
tumorigenesis, including Nanog [7], CoREST [32], and
HDAC3 and HDAC4 [33]. Thus, it is possible that FASN
expression is indirectly controlled by NAC1 through binding
with its speciﬁc partner(s). Identiﬁcation of the NAC1-FASN
pathway sheds new light on the molecular mechanism by
which NAC1 promotes tumor progression. Further studies
are required to elucidate the transcriptional regulation of
FASN by NAC1.Journal of Oncology 9
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Figure 4: C93 treatment promotes apoptosis in ovarian cancer cells including cells that are resistant to carboplatin and paclitaxel. (a) In
three ovarian cancer cell lines, C93 at its IC50 concentration increases the percentage of annexin V stained cells in a time dependent fashion.
DMSO was used as the vehicle control. (b) C93 also increases annexin V stained cells in carboplatin resistant (CR) and paclitaxel resistant
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The second ﬁnding in the current study involves the
positive correlation between FASN expression and recur-
rence status in ovarian serous carcinoma tissue. It has been
shown that ectopic overexpression of FASN results in drug
resistance and that reducing the FASN expression increased
the drug sensitivity in breast cancer cell lines [34]. At low
concentrations, FASN inhibitor also sensitized tumor cells
with FASN overexpression to chemotherapeutic agents [34,
35]. The FASN-mediated drug resistance appears to be due
to a decrease in drug-induced apoptosis due to abundant
palmiticacidasaresultofFASNoverexpression[34].Despite
recent advances in discovering drug-resistance biomarkers
that are associated with recurrent and chemoresistant ovar-
ian cancer [1, 3, 15, 36–41], reversing drug resistance by
targeting these markers remains a tantalizing objective. The
problemliesinthelackofreagentsthatcanbeusedtoinhibit
these genes in clinical studies. Thus, therapeutic targeting
of FASN provides an attractive option since selective small
compound inhibitors for this protein are available. The ﬁrst
generation of FASN inhibitors, including C75 and Orlistat,10 Journal of Oncology
potentlyinhibitedtumorgrowthinamousexenograftmodel
but the adverse eﬀects associated with these drugs prevented
their further consideration for clinical applications [23]. On
the other hand, C93, the second generation FASN inhibitor
usedinthisstudy,pharmacologicallyeliminatesconcomitant
CPT-1 stimulation and does not induce the anorexia and
feeding behavior changes in mice that were caused by earlier
generation FASN inhibitors [28, 42]. These features are
importantforanyFASNinhibitorbeforeitcanbeconsidered
for clinical testing. Our in vitro studies demonstrate that
C93 aﬀects both carboplatin and paclitaxel resistant ovarian
cancer cells. Thus, ovarian cancer cells that overexpress
FASN are molecularly dependent on it for cell survival. This
observation is signiﬁcant because FASN inhibitors provide
an alternative treatment for ovarian cancer patients who
have developed recurrent tumors after initial paclitaxel and
carboplatin treatment.
The antitumor eﬀects of FASN inhibitors, like C93,
are thought to result from depletion of end product fatty
acids with accumulation of toxic intracellular malonyl-CoA
and altered production of phospholipids with diminished
membrane synthesis [23, 43]. Alternatively, FASN inhibitors
may suppress tumors through metabolism-independent
mechanisms. For example, FASN inhibition has been shown
to selectively activate AMP-activated protein kinase (AMPK)
in ovarian cancer cells causing cytotoxicity while sparing
most normal human tissues from these pleiotropic eﬀects of
AMPK activation [28]. Moreover, a positive feedback regu-
lation has been reported in ovarian carcinoma cells between
AKT activation and FASN expression [44]. Phosphorylated
AKT signiﬁcantly correlates with FASN expression and
FASN inhibition by either C75 or cerulenin downregulates
phosphorylated AKT [44–46]. Therefore, FASN inhibitors
may contribute to antioncogenesis by suppressing tumor-
promoting signaling pathways such as AKT, a pathway that
is frequently activated in ovarian serous carcinoma [47].
Thus, the C93-induced apoptosis in ovarian cancer cells
may be related to FASN inactivation and/or suppression of
AKT activity. It has been demonstrated that FASN inhibition
initiates apoptosis more eﬀectively in neoplastic cells with
mutant TP53 than in those with wild-type TP53 [27, 48].
Our current ﬁnding supports this view as the A2780 cell line
that harbors wild-type TP53 [49] responds to C93 with cell
cycle arrest in the G1 phase in addition to apoptosis, while
both the SKOV3 and OVCAR3 cell lines with their deleted
andmutatedTP53,respectively,respondtoC93withmassive
apoptosis [50]. Since mutated TP53 appears in the majority
of ovarian high-grade serous carcinomas [1, 51], it is likely
that apoptosis is the predominant antitumor mechanism of
FASN inhibition.
As with other epithelial cancers of the breast, colon,
and prostate [20, 21, 52], FASN overexpression in ovar-
ian cancer, as this study shows, appears to be associated
with the most malignant type, that is, high-grade serous
carcinoma. More importantly, in patients with this cancer,
the level of FASN expression signiﬁcantly correlates with
worse clinical outcome, supporting the view that FASN
expression contributes to disease aggressiveness in cancer
cells. A similar observation has been reported for NAC1
[3, 15], hence suggesting that the NAC1-FASN pathway con-
stitutes one of the mechanisms that propels ovarian cancer
progression.HowFASNcontributestodiseaseaggressiveness
in ovarian cancer remains speculative. Besides endowing
drug resistance, FASN may enhance oncogenesis via cellular
mechanisms such as enhancing the Wnt [53], c-Met [54],
and proteosome pathways [55]. Moreover, upregulation of
FASN gives cancer cells a growth and survival advantage by
blocking apoptosis under hypoxia, a common condition in
solid tumors and tumor eﬀusions [56, 57].
In summary, this study identiﬁed candidate proteins
controlled by NAC1 and provides new evidence that FASN
expression is at least in part regulated by NAC1. Thus the
NAC1-FASN pathway may represent a new mechanism for
tumor progression that creates ovarian tumor cells that
are resistant to chemotherapy. Our ﬁndings also indicate
that FASN is a novel biomarker for recurrent ovarian
serous carcinoma and its enzyme activity is essential for
the survival of chemoresistant tumor cells. New generation
FASN inhibitors, like C93, deserve consideration in future
clinical trials involving advanced ovarian serous carcinomas,
particularly those that are refractory to paclitaxel and plat-
inum drugs. Further studies will be required to delineate the
biological and translational roles of FASN in drug resistance
in ovarian and perhaps other types of cancers.
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FASN: Fatty acid synthase.
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